Christopher Goebel

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

J. Maciejewski, H. Carraway, A. Advani, 2018, Blood Cancer Journal.

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype

R. Fox, R. Bermel, A. Goodman, 2021, Annals of clinical and translational neurology.

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study

Kunio Nakamura, R. Fox, S. Narayanan, 2020, Neurology.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

J. Maciejewski, H. Carraway, A. Advani, 2018, Blood Cancer Journal.